[11] The small G protein RAS, the protein kinase RAF, and PI3K have central roles as intracellular mediators of EGFR signaling (Fig. 1) Overexpression of EGFR may be detected in up to 90% of ...

We have identified a number of potential downstream targets of Egfr signaling during egg development (via a microarray screen comparing gene expression in ovaries in which the Egfr pathway was up or ...

Lin Han obtained his BE degree from Tsinghua University in Beijing, P. R. China, and his PhD degree from the Massachusetts Institute of Technology in the area of Bio- and Polymeric Materials. After ...

Let’s take a look at how differential signaling is different from single ended, and what that means for engineers and for users. Collectively, standards like TTL, CMOS, and LVTTL are known as ...

We have studied the oncogenic role of the FAM83 proteins in a variety of cancers and are continuing to define the molecular interactions between the FAM83 proteins and EGFR/RAS signaling effectors, ...

and novel agents (e.g. tirapazamine, EGFR inhibitors and other targeted agents) with radiotherapy will be examined. This article is part one of two articles. In the subsequent article, the general ...

In this GEN webinar, Shyra Gardai, PhD, will demonstrate the potential of the novel extracellular degrading platform, EpiTACs ...

The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...

4,8-9 Patients with EGFRm NSCLC are particularly sensitive to treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) which blocks the cell-signaling pathways that drive the growth of tumor cells.